Senetek terminate license agreement with Ardana for Invicorp « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Senetek terminate license agreement with Ardana for Invicorp

Posted on July 7, 2008 by crimsoncanary

Senetek have terminated a license agreement with Ardana for Invicorp due to Ardana’s entry into voluntary administration on June 27, 2008.

Filed under: gpcr | Tagged: agonist, Alpha adrenoreceptor, antagonist, aviptadil, Invicorp, Licensing, phentolamine mesylate, Resurgam, Vasoactive intestinal polypeptide, Vasopotin, VIP

« Movetis Vasopressin 2 antagonist M0002 enters Phase IIb trials for cirrhotic ascites Shire to acquire Jerini adding Bradykinin antagonist Icatibant to portfolio »

Leave a Reply